Literature DB >> 7629551

Transferable resistance to cefotaxime in nosocomial Klebsiella pneumoniae and Escherichia coli strains due to their production of extended-spectrum beta-lactamase in Slovakia.

M Hupková1, J Blahová, M Babálová, V Krcméry, K Králiková.   

Abstract

Transferable resistance to cefotaxime was demonstrated in 21 nosocomial strains of Klebsiella pneumoniae and Escherichia coli subsequently isolated from patients in two large University clinics. Using the double-disk diffusion test, we could detect, in each such strain, as well as in E. coli 3110 K-12 transconjugants after the transfer, the production of an Extended Spectrum Beta-Lactamase (ESBL). Ceftibuten was demonstrated to be effective against the majority of strains studied.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629551     DOI: 10.1179/joc.1995.7.1.16

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  4 in total

1.  Extended spectrum beta-lactamase reactions in Stenotrophomonas maltophilia.

Authors:  J Blahová; M Hupková-Lesická; K Králiková; V Krcméry
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

2.  Transferable resistance to cefotaxime, ceftazidime, and aztreonam and production of extended-spectrum beta-lactamase in a strain of Salmonella enteritidis.

Authors:  J Blahová; K Králiková; V Krcméry; K Kubonová
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

3.  Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates.

Authors:  K R Forward; D E Low; M Laverdiere; R Rennie; A E Simor; P A Franks
Journal:  Can J Infect Dis       Date:  1997-05

Review 4.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.